✍ Scribed by Erik De Clercq
No coin nor oath required. For personal study only.
This review article presents the fourth part (part D) in the series of stories on antiviral drug discovery. The stories told in part D focus on: (i) the cyclotriazadisulfonamide compounds; (ii) the {5‐[(4‐bromophenylmethyl]‐2‐phenyl‐5__H__‐imidazo[4,5‐c]pyridine} compounds; (iii) (1__H__,3__H__‐thiazolo[3,4‐a]benzimidazole) derivatives; (iv) T‐705 (6‐fluoro‐3‐hydroxy‐2‐pyrazinecarboxamide) and (v) its structurally closely related analogue pyrazine 2‐carboxamide (pyrazinamide); (vi) new strategies for the treatment of hemorrhagic fever virus infections, including, as the most imminent, (vii) dengue fever, (viii) the veterinary use of acyclic nucleoside phosphonates; (ix) the potential (off‐label) use of cidofovir in the treatment of papillomatosis, particularly RRP (recurrent respiratory papillomatosis); and (x) finally, the prophylactic use of tenofovir to prevent HIV infections. © 2009 Wiley Periodicals, Inc. Med Res Rev, 30, No. 4, 667–707, 2010
📜 SIMILAR VOLUMES
## Abstract The ten stories told here deal with (i) ribavirin as an inhibitor of IMP dehydrogenase and (ii) ribavirin, in combination with pegylated interferon, as the present “standard of care” for hepatitis C; (iii) __S__‐adenosylhomocysteine hydrolase inhibitors as antiviral agents; (iv) new ada
## Abstract This review article presents the fifth part (part E) in the series of stories on antiviral drug discovery. The ten stories belonging to this fifth part are dealing with (i) aurintricarboxylic acid; (ii) alkenyldiarylmethanes; (iii) human immunodeficiency virus (HIV) integrase inhibitors